CLAIMS

What is claimed is:

1. A composition comprising:

(a) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises a V_H CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72); a V_H CDR2 region comprising the amino acid sequence of FIYYGGNTKYNPSLKS (SEQ ID NO: 74); a V_H CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76); a V_L CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59); a V_L CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); and a V_L CDR3 region comprising the amino acid sequence of QQSYSPPLT (SEQ ID NO: 63); and

(b) an oseltamivir composition.

2. A composition comprising:

(a) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises a V_H CDR1 region comprising the amino acid sequence of SNYMS (SEQ ID NO: 103); a V_H CDR2 region comprising the amino acid sequence of VIYSGGSTYYADSVK (SEQ ID NO: 105); a V_H CDR3 region comprising the amino acid sequence of CLSRMRGYGLDV (SEQ ID NO: 107); a V_L CDR1 region comprising the amino acid sequence of RTSQSISSYLN (SEQ ID NO: 92); a V_L CDR2 region comprising the amino acid sequence of AASSLQSGVPSRF (SEQ ID NO: 94); and a V_L CDR3 region comprising the amino acid sequence of QQSYSMPA (SEQ ID NO: 96); and

(b) an oseltamivir composition.

3. A pharmaceutical composition comprising the composition of claim 1 or 2 and a pharmaceutical carrier.

4. The composition of any one of claims 1-3, wherein said oseltamivir is oseltamivir phosphate.

5. The composition of any one of claims 1-3, further comprising a second anti-influenza A antibody.

6. The composition of claim 5, wherein said second anti-influenza A antibody is an anti-M2e antibody or an anti-HA antibody.

7. The composition of any one of claims 1-3 for use in the treatment or prevention of an influenza virus infection in a subject.

8. The composition of claim 7, wherein said anti-M2e antibody in the composition is formulated for use at a dosage of between 10 and 40 mg/kg/day.

9. The composition of claim 8, wherein said anti-M2e antibody in the composition is formulated for use once or twice per day.

10. The composition of claim 7, wherein said oseltamivir composition in the composition is formulated for use at a dosage of 10 mg/kg.

11. The composition of claim 10, wherein said oseltamivir composition in the composition is formulated for use once or twice per day.

12. The composition of claim 7, wherein said anti-M2e antibody or said oseltamivir composition in the composition is formulated for use prior to influenza infection.

13. The composition of claim 7, wherein said anti-M2e antibody or said oseltamivir composition in the composition is formulated for use after influenza infection.

14. The composition of claim 13, wherein said anti-M2e antibody in the composition is formulated for use within 4 days or 48 hours after influenza infection.

15. The composition of claim 7, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable either simultaneously or sequentially.

16. The composition of claim 15, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable sequentially, and wherein said anti-M2e antibody is administrable before said oseltamivir composition.

17. The composition of claim 15, wherein said composition is formulated such that said anti-M2e antibody and said oseltamivir composition are administrable sequentially, and wherein said anti-M2e antibody is administrable after said oseltamivir composition.

18. Use of the composition of any one of claims 1-3 in the manufacture of a medicament for the treatment or prevention of an influenza virus infection in a subject.

19. The use of claim 18, wherein said anti-M2e antibody in the medicament is formulated for use at a dosage of between 10 and 40 mg/kg/day.

20. The use of claim 19, wherein said anti-M2e antibody in the medicament is formulated for use once or twice per day.

21. The use of claim 18, wherein said oseltamivir composition in the medicament is formulated for use at a dosage of 10 mg/kg.

22. The use of claim 21, wherein said oseltamivir composition in the medicament is formulated for use once or twice per day.

23. The use of claim 18, wherein said anti-M2e antibody or said oseltamivir composition in the medicament is formulated for use prior to influenza infection.

24. The use of claim 18, wherein said anti-M2e antibody or said oseltamivir composition in the medicament is formulated for use after influenza infection.

25. The use of claim 24, wherein said anti-M2e antibody in the medicament is formulated for use within 4 days or 48 hours after influenza infection.

26. The use of claim 18, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used simultaneously or sequentially.

27. The use of claim 26, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used before said oseltamivir composition.

28. The use of claim 26, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used after said oseltamivir composition.

29. A kit comprising the composition of claim 3.

CLAIMS

1. Use of a composition comprising:

(a) either

(1) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises

a V_H CDR1 region comprising the amino acid sequence of NYYWS (SEQ ID NO: 72);
a V_H CDR2 region comprising the amino acid sequence of
FIYYGGNTKYNPSLKS (SEQ ID NO: 74);
a V_H CDR3 region comprising the amino acid sequence of ASCSGGYCILD (SEQ ID NO: 76);
a V_L CDR1 region comprising the amino acid sequence of RASQNIYKYLN (SEQ ID NO: 59);
a V_L CDR2 region comprising the amino acid sequence of AASGLQS (SEQ ID NO: 61); and
a V_L CDR3 region comprising the amino acid sequence of QQSYSPPLT (SEQ ID NO: 63);

or

(2) an isolated fully human monoclonal anti-M2e antibody composition, wherein the antibody comprises

a V_H CDR1 region comprising the amino acid sequence of SNYMS (SEQ ID NO: 103);
a V_H CDR2 region comprising the amino acid sequence of
VIYSGGSTYYADSVK (SEQ ID NO: 105);
a V_H CDR3 region comprising the amino acid sequence of CLSRMRGYGLDV (SEQ ID NO: 107);
a V_L CDR1 region comprising the amino acid sequence of RTSQSISSYLN (SEQ ID NO: 92);
a V_L CDR2 region comprising the amino acid sequence of AASSLQSGVPSRF (SEQ ID NO: 94); and
a V_L CDR3 region comprising the amino acid sequence of QQSYSMPA (SEQ ID NO: 96);

and

(b) an oseltamivir composition;

in the manufacture of a medicament for the treatment or prevention of an influenza virus infection in a subject, wherein said anti-M2e antibody or said oseltamivir composition is provided within 4 days after influenza infection.

2. The use of claim 1, wherein said composition further comprises a pharmaceutical carrier.

3. The use of claim 1 or 2, wherein said oseltamivir is oseltamivir phosphate.

4. The use of any one of claims 1-3, wherein the composition further comprises a second anti-influenza A antibody.

5. The use of claim 4, wherein said second anti-influenza A antibody is an anti-M2e antibody or an anti-HA antibody.

6. The use of claim 1, wherein said anti-M2e antibody in the medicament is formulated for use at a dosage of between 10 and 40 mg/kg/day.

7. The use of claim 6, wherein said anti-M2e antibody in the medicament is formulated for use once or twice per day.

8. The use of claim 1, wherein said oseltamivir composition in the medicament is formulated for use at a dosage of 10 mg/kg.

9. The use of claim 8, wherein said oseltamivir composition in the medicament is formulated for use once or twice per day.

10. The use of claim 1, wherein said anti-M2e antibody in the medicament is formulated for use within 48 hours after influenza infection.

11. The use of claim 1, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used simultaneously or sequentially.

12. The use of claim 11, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used before said oseltamivir composition.

13. The use of claim 11, wherein said medicament is formulated such that said anti-M2e antibody and said oseltamivir composition are used sequentially, and wherein said anti-M2e antibody is used after said oseltamivir composition.